A Phase 1 Study to Investigate the Mass Balance of [14C]-Nanatinostat and to Evaluate the Relative Bioavailability of Nanatinostat in Patients With Selected Advanced Cancers
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Nanatinostat/valganciclovir combination therapy (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Viracta Therapeutics
Most Recent Events
- 20 Jan 2025 Status changed from recruiting to discontinued.(Reason the study was stopped: Sponsor Decision).
- 18 Mar 2024 Status changed from not yet recruiting to recruiting.
- 11 Mar 2024 New trial record